Affordable Access

Access to the full text

Ranibizumab

Authors
  • Blick, Stephanie K. A.1, 2
  • Keating, Gillian M.1, 2
  • Wagstaff, Antona J.1, 2
  • 1 Wolters Kluwer Health / Adis, 41 Centorian Drive, Mairangi Bay, North Shore, Auckland, 0754, New Zealand , Mairangi Bay, North Shore, Auckland (New Zealand)
  • 2 Wolters Kluwer Health, Conshohocken, Pennsylvania, USA , Conshohocken (United States)
Type
Published Article
Journal
Drugs
Publisher
Springer International Publishing
Publication Date
Jun 01, 2007
Volume
67
Issue
8
Pages
1199–1206
Identifiers
DOI: 10.2165/00003495-200767080-00007
Source
Springer Nature
Keywords
License
Yellow

Abstract

▴ Ranibizumab is the antigen-binding fragment of a recombinant, humanised monoclonal antibody, which binds with high affinity to, and inhibits the activity of, all active forms of vascular endothelial growth factor A, an important mediator in the development of choroidal neovascularisation. ▴ Well designed, phase III trials in patients with neovascular (wet) age-related macular degeneration (AMD) indicated that monthly intravitreal injections of ranibizumab 0.3 or 0.5mg for up to 2 years maintained or improved visual acuity to a greater extent than sham injection, verteporfin photodynamic therapy or sham photodynamic therapy.▴ In patients with predominantly classic wet AMD who received ranibizumab in combination with verteporfin therapy, preliminary results indicate that combination therapy is superior to that of verteporfin therapy alone.▴ Most serious ocular adverse events, which were uncommon, were associated with either the injection procedure or ranibizumab.

Report this publication

Statistics

Seen <100 times